{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:52:55Z","timestamp":1784173975117,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.yebeh.2019.05.039","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:45:11Z","timestamp":1568375111000},"page":"106344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"PA","title":["Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study"],"prefix":"10.1016","volume":"100","author":[{"given":"Florentina M.E.","family":"Pinckaers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mebeline E.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian H.J.M.","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.05.039_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-14-75","article-title":"The prevalence of psychosis in epilepsy; a systematic review and meta-analysis","volume":"14","author":"Clancy","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.yebeh.2019.05.039_bb0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1192\/bjp.152.2.246","article-title":"Post-ictal psychoses. A clinical and phenomenological description","volume":"152","author":"Logsdail","year":"1988","journal-title":"Br J Psychiatry"},{"issue":"10","key":"10.1016\/j.yebeh.2019.05.039_bb0015","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/brain\/aww196","article-title":"Psychotic disorders induced by antiepileptic drugs in people with epilepsy","volume":"139","author":"Chen","year":"2016","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.039_bb0020","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.039_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1517\/14740338.6.3.241","article-title":"The safety of levetiracetam","volume":"6","author":"Sirsi","year":"2007","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.039_bb0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","article-title":"Comparative retention rates and long-term tolerability of new antiepileptic drugs","volume":"16","author":"Chung","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.039_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.039_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.yebeh.2019.05.039_bb0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.039_bb0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.yebeh.2012.01.012","article-title":"Impact of antiepileptic drugs on genesis of psychosis","volume":"23","author":"Noguchi","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.039_bb0055","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.039_bb0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2019.05.039_bb0065","first-page":"1069","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010"},{"issue":"1","key":"10.1016\/j.yebeh.2019.05.039_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","article-title":"Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam","volume":"13","author":"Mula","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.039_bb0075","series-title":"Prediction tools for psychiatric adverse effects after levetiracetam prescription","author":"Josephson","year":"2019"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2019.05.039_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.schres.2004.07.004","article-title":"Febrile seizures and risk of schizophrenia","volume":"73","author":"Vestergaard","year":"2005","journal-title":"Schizophr Res"},{"issue":"12","key":"10.1016\/j.yebeh.2019.05.039_bb0085","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1528-1167.2007.01262.x","article-title":"Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam","volume":"48","author":"Mula","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2019.05.039_bb0090","first-page":"699","article-title":"Prevalence and etiology of epilepsy in a Norwegian county\u2014a population based study","volume":"56","author":"Syvertsen","year":"2015"},{"key":"10.1016\/j.yebeh.2019.05.039_bb0095","first-page":"630853","article-title":"A review of the epidemiology of temporal lobe epilepsy","volume":"2012","author":"T\u00e9llez-Zenteno","year":"2012","journal-title":"Epilepsy Res Treat"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:30:36Z","timestamp":1761503436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019303117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":19,"alternative-id":["S1525505019303117"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.039","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106344"}}